Pyrrolidine and bicycloheteroaryl containing oga inhibitor compounds

Inventor: José Manuel Bartolomé-Nebreda, Andrés Avelino TRABANCO-SUÁREZ, Ana Isabel De Lucas Olivares, Sergio-Alvar Alonso-De Diego

• Assignee: Janssen Pharmaceutica Nv

The present invention relates to O-GIcNAc hydrolase (OGA) inhibitors. The invention is also directed to pharmaceutical compositions comprising such compounds, to processes for preparing such compounds and compositions, and to the use of such compounds and compositions for the prevention and treatment of disorders in which inhibition of OGA is beneficial, such as tauopathies, in particular Alzheimer’s disease or progressive supranuclear palsy; and neurodegenerative diseases accompanied by a tau pathology, in particular amyotrophic lateral sclerosis or frontotemporal lobe dementia caused by C90RF72 mutations; or alpha synucleinopathies, in particular Parkinson’s disease, dementia due to Parkinson’s (or neurocognitive disorder due to Parkinson’s disease), dementia with Lewy bodies, multiple system atrophy, or alpha synucleinopathy caused by Gaucher’s disease.

Read the publication that featured this abstract